CardiaCures, Inc
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Cardiovascular
CardiaCures is a cardiovascular drug company developing software-linked medicines: drug-led combination products in which precision-dosing software and wearable monitoring are designed to be integrated into prescribing workflow and the FDA-approved label. The company’s two FDA-engaged lead programs target high-need arrhythmia settings: a genetically defined inherited arrhythmia program that offers a focused first NDA path, and an atrial fibrillation rhythm-control program designed to address dosing, QT monitoring, and initiation barriers that limit current antiarrhythmic use. CardiaCures is powered by the Translational Cures platform and led by former FDA leaders and drug-development executives.
.jpeg)
Company HQ City:
Washington
Company HQ State:
DC
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
Primary program: an FDA-engaged drug-led combination product for inherited arrhythmia, integrating a known small-molecule therapy with the CURES precision-dosing system. Second lead program: an FDA-engaged atrial-fibrillation rhythm-control product designed to address dosing, biomarker monitoring, and initiation barriers. Both are intended for 505(b)(2) NDA pathways.
CEO
David Strauss
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
2 lead product programs; broader platform collaborations available.
When you expect your next catalyst update?
January, 2027
What is your next catalyst (value inflection) update?
Initiation of the first registration-enabling clinical program for the inherited-arrhythmia product. In parallel, advancement of the atrial-fibrillation program through the FDA's model-informed drug development (MIDD) pathway.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}